COMP <GO>
OMDA vs USPH // ENTERPRISE SCALE & MARKET CAP
Omada Health Inc. (NASDAQ) VS. U.S. Physical Therapy Inc. (NYSE) • 15-METRIC TALLY: OMDA 3
— USPH 8
▲ ENTERPRISE SCALE & MARKET CAP LEADER: USPH
LAST: $18.73 (-4.68%) • MKT CAP: $1.20B
market-cap
$1.20B
LAST: $85.83 (-0.85%) • MKT CAP: $1.29B
market-cap
$1.29B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OMDA VS. USPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OMDA | USPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.70% | 19.20% | +46.50 | OMDA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -15.70% | 11.50% | -27.20 | USPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.41% | 5.81% | -4.40 | USPH | /fcf-yield <GO> |
| Operating Margin | -4.60% | 11.10% | -15.70 | USPH | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 5.10% | -10.00 | USPH | /net-margins <GO> |
| Revenue Growth (YoY) | 53.20% | 16.30% | +36.90 | OMDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.12% | -2.12 | USPH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.93 | 2.94 | +5.99 | OMDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | USPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.9 | 54.7 | -4.80 | USPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 27.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.20B | $1.29B | -$88.9M | USPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OMDA REV | USPH REV | OMDA GROSS % | USPH GROSS % | OMDA FCF | USPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $260.2M | $781.0M | 65.7% | 19.2% | $16.9M | $75.1M |
| FY 2024 | $169.8M | $671.3M | 60.6% | 18.5% | -$34.8M | $74.9M |
| FY 2023 | $122.8M | $604.8M | — | — | -$49.7M | $82.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OMDA // BETA —
USPH // BETA —